Genmab — December 2018
-
Alt godt til dem som venter (og er tro mod deres investeringsstrategi): https://play.borsen.dk/klip/5c0565b4595ab4f00a32b277/genmab-analyse_fuld_fokus_paa_darzalex-data_senere_i_dag.html
-
Hvis det er 16.30 dansk tid bliver luk måske meget int.
-
Amgen antibody shows promise in myeloma trial, gets FDA fast track https://www.reuters.com/article/us-amgen-myeloma/amgen-antibody-shows-promise-in-myeloma-trial-gets-fda-fast-track-idUSKBN1O305Z?feedType=RSS&feedName=healthNews
-
-
-
Rigtigt Bulder og fra artiklen i Børsen "Han pegede også på, at over 44 pct. af patienterne i studiet var over 75 år, hvilket er usædvanligt højt for sådan et studie, og er med til at understrege de imponerende resultater med Darzalex.
"Vi har patienter, der minimum er kræftfrie i fire år, hvilket er meget imponerende," siger Dr. Nizar Bahlis fra University of Calgary, der præsenterede data fra studierne Pollux og Castor, der også fremhævede, at overlevelsen generelt var meget høj,
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind